Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.71
NAS:TTOO's Cash-to-Debt is ranked lower than
63% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. NAS:TTOO: 0.71 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:TTOO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.71  Med: 1.95 Max: 6.86
Current: 0.71
0.71
6.86
Equity-to-Asset -0.24
NAS:TTOO's Equity-to-Asset is ranked lower than
89% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NAS:TTOO: -0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:TTOO' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.81  Med: 0.44 Max: 0.67
Current: -0.24
-2.81
0.67
Debt-to-Equity -4.16
NAS:TTOO's Debt-to-Equity is ranked lower than
93% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. NAS:TTOO: -4.16 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:TTOO' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.16  Med: 0.65 Max: 31.12
Current: -4.16
-4.16
31.12
Debt-to-EBITDA -0.85
NAS:TTOO's Debt-to-EBITDA is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. NAS:TTOO: -0.85 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:TTOO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.85  Med: -0.71 Max: -0.27
Current: -0.85
-0.85
-0.27
Piotroski F-Score: 3
Altman Z-Score: -9.90
Beneish M-Score: -3.97
WACC vs ROIC
14.59%
-1010.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -863.85
NAS:TTOO's Operating Margin % is ranked lower than
93% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. NAS:TTOO: -863.85 )
Ranked among companies with meaningful Operating Margin % only.
NAS:TTOO' s Operating Margin % Range Over the Past 10 Years
Min: -77121.05  Med: -4472.62 Max: -863.85
Current: -863.85
-77121.05
-863.85
Net Margin % -1004.62
NAS:TTOO's Net Margin % is ranked lower than
94% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. NAS:TTOO: -1004.62 )
Ranked among companies with meaningful Net Margin % only.
NAS:TTOO' s Net Margin % Range Over the Past 10 Years
Min: -76078.95  Med: -4679.07 Max: -1004.62
Current: -1004.62
-76078.95
-1004.62
ROE % -635.16
NAS:TTOO's ROE % is ranked lower than
90% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. NAS:TTOO: -635.16 )
Ranked among companies with meaningful ROE % only.
NAS:TTOO' s ROE % Range Over the Past 10 Years
Min: -635.16  Med: -127.04 Max: -90.63
Current: -635.16
-635.16
-90.63
ROA % -99.05
NAS:TTOO's ROA % is ranked lower than
85% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. NAS:TTOO: -99.05 )
Ranked among companies with meaningful ROA % only.
NAS:TTOO' s ROA % Range Over the Past 10 Years
Min: -126.45  Med: -74.3 Max: -54.58
Current: -99.05
-126.45
-54.58
ROC (Joel Greenblatt) % -423.53
NAS:TTOO's ROC (Joel Greenblatt) % is ranked lower than
75% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. NAS:TTOO: -423.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:TTOO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1702.72  Med: -936.49 Max: -419.72
Current: -423.53
-1702.72
-419.72
3-Year Revenue Growth Rate 118.00
NAS:TTOO's 3-Year Revenue Growth Rate is ranked lower than
73% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NAS:TTOO: 118.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:TTOO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 98.7  Med: 113.9 Max: 118
Current: 118
98.7
118
3-Year EBITDA Growth Rate 22.90
NAS:TTOO's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NAS:TTOO: 22.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:TTOO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 22.9 Max: 41.7
Current: 22.9
-8.6
41.7
3-Year EPS without NRI Growth Rate 22.40
NAS:TTOO's 3-Year EPS without NRI Growth Rate is ranked higher than
91% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NAS:TTOO: 22.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:TTOO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -11.3  Med: 22.4 Max: 45.8
Current: 22.4
-11.3
45.8
GuruFocus has detected 2 Warning Signs with T2 Biosystems Inc NAS:TTOO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:TTOO's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

TTOO Guru Trades in Q2 2017

Julian Robertson 1,737,085 sh (+27.34%)
» More
Q3 2017

TTOO Guru Trades in Q3 2017

Steven Cohen 150,000 sh (New)
Jim Simons 48,500 sh (New)
Julian Robertson 1,994,685 sh (+14.83%)
» More
Q4 2017

TTOO Guru Trades in Q4 2017

Jim Simons 83,500 sh (+72.16%)
Julian Robertson 2,321,800 sh (+16.40%)
Steven Cohen 150,000 sh (unchged)
» More
Q1 2018

TTOO Guru Trades in Q1 2018

Jim Simons 170,200 sh (+103.83%)
Steven Cohen 148,500 sh (-1.00%)
Julian Robertson 2,017,572 sh (-13.10%)
» More
» Details

Insider Trades

Latest Guru Trades with TTOO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Julian Robertson 2018-03-31 Reduce -13.10%0.2%$4.21 - $7 $ 7.0531%2,017,572
Julian Robertson 2017-12-31 Add 16.40%0.21%$3.73 - $4.6 $ 7.0571%2,321,800
Julian Robertson 2017-09-30 Add 14.83%0.2%$2.52 - $6.78 $ 7.0591%1,994,685
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:XKRX:086040, TSX:AKU.U, NAS:FLDM, NAS:CTSO, ISX:PRDA, AMEX:PTN, NAS:CDNA, OSTO:IMMNOV, NAS:QTNT, HKSE:08037, NAS:MGEN, ASX:IDX, TSE:4595, TSE:4978, MEX:MEDICA B, NYSE:ENZ, TSE:4671, XMCE:CBAV, LSE:MXCT, LSE:EKF » details
Traded in other countries:3T2.Germany,
Headquarter Location:USA
T2 Biosystems Inc is an in vitro diagnostic company. It has developed the proprietary platform that enables direct detection of pathogens, biomarkers and other abnormalities across various unpurified patient sample types.

T2 Biosystems Inc provides rapid in vitro diagnostic tests. Its panels are focused on bacterial sepsis infections, hemostasis, and Lyme disease. Its core technology is the T2 magnetic resonance platform, which can detect a variety of targets, including DNA, proteins, and hemostasis measurements. Using this technology, the firm has also developed the T2Dx, a benchtop instrument that can be used to detect sepsis and Lyme disease, among other applications. The T2Dx is fully automated from patient sample to result and includes panels for Candida and other bacteria that can lead to sepsis.

Ratios

vs
industry
vs
history
PS Ratio 40.07
TTOO's PS Ratio is ranked lower than
95% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. TTOO: 40.07 )
Ranked among companies with meaningful PS Ratio only.
TTOO' s PS Ratio Range Over the Past 10 Years
Min: 19.41  Med: 45.42 Max: 4915
Current: 40.07
19.41
4915
EV-to-EBIT -6.07
TTOO's EV-to-EBIT is ranked lower than
99.99% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. TTOO: -6.07 )
Ranked among companies with meaningful EV-to-EBIT only.
TTOO' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.8  Med: -3.9 Max: -1.5
Current: -6.07
-12.8
-1.5
EV-to-EBITDA -6.40
TTOO's EV-to-EBITDA is ranked lower than
99.99% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. TTOO: -6.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
TTOO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.1  Med: -4.05 Max: -1.5
Current: -6.4
-13.1
-1.5
EV-to-Revenue 52.39
TTOO's EV-to-Revenue is ranked lower than
93% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. TTOO: 52.39 )
Ranked among companies with meaningful EV-to-Revenue only.
TTOO' s EV-to-Revenue Range Over the Past 10 Years
Min: 19.4  Med: 46.8 Max: 3311.3
Current: 52.39
19.4
3311.3
Current Ratio 0.65
TTOO's Current Ratio is ranked higher than
80% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. TTOO: 0.65 )
Ranked among companies with meaningful Current Ratio only.
TTOO' s Current Ratio Range Over the Past 10 Years
Min: 0.65  Med: 5.4 Max: 14.56
Current: 0.65
0.65
14.56
Quick Ratio 0.61
TTOO's Quick Ratio is ranked higher than
83% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TTOO: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
TTOO' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 5.28 Max: 14.54
Current: 0.61
0.61
14.54
Days Inventory 33.01
TTOO's Days Inventory is ranked higher than
67% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. TTOO: 33.01 )
Ranked among companies with meaningful Days Inventory only.
TTOO' s Days Inventory Range Over the Past 10 Years
Min: 32.58  Med: 39.46 Max: 83.7
Current: 33.01
32.58
83.7
Days Sales Outstanding 35.19
TTOO's Days Sales Outstanding is ranked higher than
79% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. TTOO: 35.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
TTOO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.25  Med: 42.21 Max: 616.51
Current: 35.19
29.25
616.51
Days Payable 20.79
TTOO's Days Payable is ranked lower than
66% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. TTOO: 20.79 )
Ranked among companies with meaningful Days Payable only.
TTOO' s Days Payable Range Over the Past 10 Years
Min: 19.66  Med: 51.1 Max: 257.6
Current: 20.79
19.66
257.6

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.50
TTOO's 3-Year Average Share Buyback Ratio is ranked lower than
97% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. TTOO: -21.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TTOO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -160.9  Med: -32.6 Max: -21.5
Current: -21.5
-160.9
-21.5

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.88
TTOO's Price-to-Median-PS-Value is ranked lower than
56% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. TTOO: 0.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TTOO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 0.92 Max: 100.5
Current: 0.88
0.52
100.5
Earnings Yield (Greenblatt) % -16.49
TTOO's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. TTOO: -16.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TTOO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -68.8  Med: -25.75 Max: -7.8
Current: -16.49
-68.8
-7.8

More Statistics

Revenue (TTM) (Mil) $6.04
EPS (TTM) $ -1.82
Beta1.81
Volatility69.10%
52-Week Range $2.53 - 9.98
Shares Outstanding (Mil)43.14

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 11 22 61
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.37 -1.12 -0.92
EPS without NRI ($) -1.37 -1.12 -0.92
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}